[Late cutaneous porphyria revealed by estrogen administration. Therapeutic effect of A.M.P].
D000249:Adenosine Monophosphate / Q000627:therapeutic use; D000328:Adult; D003276:Contraceptives, Oral / Q000009:adverse effects; D004967:Estrogens / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D009644:Norgestrel / Q000009:adverse effects; D011164:Porphyrias / Q000175:diagnosis / Q000188:drug therapy
D003276:Contraceptives, Oral; D004967:Estrogens; D009644:Norgestrel; D000249:Adenosine Monophosphate; D004997:Ethinyl Estradiol
Porphyrie cutanée tardive révélée par administration d'oestrogènes. Effet thérapeutique de l'A.M.